Castle biosciences inc.

Castle Biosciences Inc’s price is currently down 25.04% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26.How does it work? - TissueCypher®. Clinicopathologic risk factors like age, sex, obesity, family history and expert pathology have been shown to have limited ability to predict progression to esophageal cancer. TissueCypher outperforms these risk factors and provides physicians with an actionable risk score and the patient’s personalized 5 ...Learn more about the Castle Biosciences Inc. lab opening. bizjournals.com. First look: Castle Biosciences celebrates grand opening of 20,000-square-foot lab in Nova Place. Biotech firm opening new 20,000-square-foot office and lab space in the North Side's Nova Place complex. 4. 5.Christopher Ballas is Chief Technology Officer at Castle Creek Biosciences, Inc. He has over 25 years of experience with cell and gene therapies in academic and industry roles covering research, development, testing, and manufacturing of viral vectors and cell therapies. Dr. Ballas recently was the Sr. Vice President of Manufacturing for Innovative …Order a test. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.

Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET. Company Participants. Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs.Founder, President and CEO. Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President, Chief Executive Officer and as a member of our board of directors since inception. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation (now Merck), Integrated ... An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.

Oct 2001 - Jul 2010 8 years 10 months. I held various positions during my employment. Some of these positions included Team Leader and staff nurse OR, temp purchasing coordinator as well as seats ...Castle Biosciences, Inc. (NASDAQ: CSTL) Castle is a commercial-stage diagnostics company, focused on providing diagnostic and prognostic testing services for dermatological cancers and mental ...

Howl’s Moving Castle is a beloved Japanese animated film that has captured the hearts of audiences worldwide since its release in 2004. Based on the novel by Diana Wynne Jones, the film tells the story of a young woman named Sophie who is c...Materials used to build castles include earth, wood and stone. Motte-and-bailey castles were made of earth and wood, but due to weaknesses in these castles, stone castles were created.CASTLE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (in thousands) Six Months Ended. June 30, 2023 2022 OPERATING ACTIVITIES Net loss $ (47,981 ) $ ...C/O CASTLE BIOSCIENCES, INC. 505 S. FRIENDSWOOD DRIVE, SUITE 401 (Street) FRIENDSWOOD: TX: 77546 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol CASTLE BIOSCIENCES INC [ CSTL] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X: Director:Castle Biosciences, Incorporated is a molecular diagnostics company that develops diagnostic and prognostic assays for rare cancers. Castle's mission is to serve individuals afflicted with rare cancers by offering accurate prognostic tests which provide information for making critical decisions regarding an individual's surveillance and ...

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes.

Castle Biosciences (NASDAQ:CSTL) has a recorded net income of -$67.14 million. CSTL has generated -$2.84 earnings per share over the last four quarters. What is Castle Biosciences's EPS forecast for next year? Castle Biosciences's earnings are expected to grow from ($3.15) per share to ($3.00) per share in the next year.

Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.Board Chairman. Daniel M. Bradbury has served as a member our board of directors since September 2012, and as chairman of our board of directors since September 2014. Mr. Bradbury is co-founder and Executive Chairman of Equillium, Inc., a publicly traded biotechnology company, where he also served as its CEO from June 2018 until January …An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide …Nov 23, 2023 · Castle Biosciences Inc’s trailing 12-month revenue is $192.0 million with a -39.3% profit margin. Year-over-year quarterly sales growth most recently was 66.2%. Analysts expect adjusted earnings to reach $-2.723 per share for the current fiscal year. Castle Biosciences Inc does not currently pay a dividend. Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes.FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will share new ...19 Feb 2022 ... Castle Biosciences, Inc., Friendswood, TX 77546, USA. 7 Department of Dermatology, University of Barcelona, IDIBAPS, 08007 Barcelona, Spain ...

Company Summary. Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle ...Castle Biosciences created a tissue repository to enable all DecisionDx-UM patients to have access to their own tumor tissue for future use. This could include taking advantage of targeted treatments, clinical trials, and further prognostic testing as they become available. Castle Biosciences is a molecular diagnostics company that provides ...DOI: 10.1200/PO.20.00119 JCO Precision Oncology no. 5 (2021) 589-601. Published online April 6, 2021.CASTLE BIOSCIENCES INC: Street Address 1 Street Address 2; 2014 SAN MIGUEL DR: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; FRIENDSWOOD: TEXAS: 77546: 281-796-9032: 3. Related Persons. Last Name First Name Middle Name; Maetzold: Derek: Street Address 1 Street Address 2; c/o Castle Biosciences, Inc.Castle Biosciences, Inc. (NASDAQ:CSTL) posted its Q2 results on August 8, reporting a GAAP loss per share of $0.06, beating expectations by $0.70. Its revenue of $34.8 million climbed 52.9% year ...

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...

Castle Biosciences, Inc., Friendswood, Texas. 629 likes · 38 talking about this. Leading diagnostics company improving health through innovative tests that guide patient care. Castle Biosciences, Inc. | Friendswood TXCastle Biosciences Company Info. Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. This Agreement and Plan of Merger (this “ Agreement”) is made and entered into as of October 18, 2021 (the “ Agreement Date”), by and among Castle Biosciences, Inc., a Delaware corporation (“ Acquirer”), Space Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Acquirer (“ Merger Sub”), Cernostics, Inc., a Delaware …Castle Biosciences is a pioneer in this field of spatial biology. Our biologically aware AI platform delivered Tissue Cypher® to the clinic, the world’s first precision medicine test to predict the risk of developing esophageal cancer in Barrett’s Esophagus patients – one of the world’s deadliest cancers. Our DecisionDx-UM Seq is a 7-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to uveal melanoma. Researchers believe that identifying mutations in tumor genes may someday help guide treatment decisions. Because the amount of tumor biopsy tissue is limited, it is important to gain as much information as ...At closing, Castle will pay $65.0 million in initial consideration to AltheaDx security holders, which will consist of $32.5 million in cash, subject to adjustments for cash, debt, transaction ...“Castle delivered a strong start to the year,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “Building on our strength and momentum from 2022, we delivered significant test report volume and revenue growth in the first quarter, which was driven by continued execution on our short- and long-term strategies.

Careers. The culture at Castle Biosciences fosters transparency, teamwork and professional growth—all while contributing to our mission to improve health outcomes for patients with dermatologic cancers using innovative technologies and research. The work of our employees directly influences our reputation and a positive experience at Castle ...

Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes. Skip to content. COVID-19 Response. Customer Service: 866-788-9007. CLINICIAN PORTAL. ORDER TEST. COVID-19 Response. ORDER TEST.

Nov 3, 2022 · Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs “Castle delivered a strong start to the year,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “Building on our strength and momentum from 2022, we delivered significant test report volume and revenue growth in the first quarter, which was driven by continued execution on our short- and long-term strategies.White Castle restaurants have operated in the United States for almost 100 years. That’s amazing enough, but the biggest shocker is that the more than 375 fast food restaurants are still completely under the company’s control. That feat is ...Nov 2, 2022 · Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.47 per share a year ago. Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx-Melanoma in patients diagnosed with cutaneous melanoma.Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q1 2022 Results - Earnings Call Transcript. SA Transcripts Mon, May 09, 2022.Castle Biosciences, Inc. 19.85. +0.47. +2.43%. Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon and welcome to Castle Biosciences ...Castle Biosciences, Inc. (CSTL) Q3 2023 Earnings Call Transcript SA Transcripts Fri, Nov. 03 Castle Biosciences GAAP EPS of -$0.26 beats by $0.50, revenue of $61.5M beats by $12.94MCastle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm …View the latest Castle Biosciences Inc. (CSTL) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Castle Biosciences, Inc is an Affirmative Action and Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability.The primary residents of European castles during the Middle Ages were the lord and lady of the realm. These might be royalty or simply the liege lords of the district where the castle was built.Castle Biosciences works with all insurance providers, including Medicare, Medicaid, commercial insurers, and the VA to secure coverage and payment for the DecisionDx-Melanoma test. Castle will submit insurance claims and manage the insurance billing process on behalf of patients. The company also sponsors an industry-leading Patient …A list of the latest Castle Biosciences Inc News - CSTL Stock News, Press Releases, Earnings Report, Financial Disclosures, Offerings, Acquisitions.Instagram:https://instagram. costco pelotonstocks buy nowbest gold buying companies1943 steel penny worth At Castle Biosciences, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. t rowe price government money fundlowest spread forex broker Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.Learn more about the Castle Biosciences Inc. lab opening. bizjournals.com. First look: Castle Biosciences celebrates grand opening of 20,000-square-foot lab in Nova Place. Biotech firm opening new 20,000-square-foot office and lab space in the North Side's Nova Place complex. 4. 5. asana stocl May 2018 - Present5 years 6 months. Baltimore, Maryland Area. 2019 Circle of Excellence Award Winner (178% to goal) 2021- 134.1% to goal. New business development of Castle Biosciences Cancer ...View the latest Castle Biosciences Inc. (CSTL) stock price, news, historical charts, analyst ratings and financial information from WSJ.